Rallybio (NASDAQ: RLYB) is a clinical-stage biotechnology company with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. Rallybio has built a pipeline of promising product candidates aimed at addressing diseases with unmet medical need in areas of complement dysregulation, hematology, and metabolic disorders. The Company’s lead program, RLYB116, is a differentiated C5 inhibitor with the potential to treat diseases of complement dysregulation. Rallybio also has two programs in preclinical development, including REV102, an ENPP1 inhibitor for the treatment of patients with hypophosphatasia (HPP), and RLYB332, a long-acting matriptase-2 antibody for the treatment of diseases of iron overload.
Rallybio is headquartered in New Haven, Connecticut.
Company Details
- Employees
- 33
- Founded
- -
- Address
- 234 Church Street,
- Phone
- (203) 859-3820
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- rallybio.com
- Keywords
- Rare Disease.
- HQ
- New Haven, Connecticut
Rallybio Questions
Rallybio's helpline number is (203) 859-3820
Rallybio's website is rallybio.com
Rallybio's LinkedIn profile is https://www.linkedin.com/company/rallybio
Rallybio has
33 employees.
View email and phone details for 33
employees at Rallybio.
Rallybio's industry is
Biotechnology Research
Rallybio's top competitors are
Modifi Bio,
Cybrexa Therapeutics,
Tempest Therapeutics,
Tango Therapeutics,
Evolveimmune Therapeutics,
Trevi Therapeutics, Inc.,
Biohaven,
Arvinas,
Halda Therapeutics,
Alphina Therapeutics.
Rallybio's categories are Biotechnology Research
Rallybio's founding year is 2018
